BioLamina

BioLamina
Developing and manufacturing laminin-based cell culture substrates for advanced cell therapies and drug discovery.
About
What does BioLamina do?
BioLamina is a Stockholm-based biotech scale-up specializing in matrix biology and cell culture. Founded in 2009, the company develops and manufactures high-quality, chemically defined, and animal-origin-free human recombinant laminin-based cell culture substrates. These substrates are designed to enable the reliable growth and differentiation of pluripotent stem cells and other primary cells, which are crucial for advancing cell therapies for serious chronic diseases and enhancing the precision…
What is BioLamina's revenue?
StartupHub estimates BioLamina's annual revenue at $5.4M (range $1.9M to $17.0M, 34% confidence), based on comparable companies in the sector.
What is BioLamina's valuation?
StartupHub estimates BioLamina's effective valuation at $156.8M (range $104.8M to $251.5M, 23% confidence), based on comparable companies in the sector.
How much funding has BioLamina raised?
BioLamina has raised a total of $42M in funding. The most recent round on record is Venture Debt.
Where is BioLamina headquartered?
BioLamina is headquartered in Stockholm, Sweden.
When was BioLamina founded?
BioLamina was founded in 2009.
What industry does BioLamina operate in?
BioLamina operates in Biotechnology, Life Sciences, HealthTech, Cell Therapy, Biotech, MedTech.
No comments yet. Be the first to share your take.
